ABSTRACT
Thrombin aggravates ischemic stroke and activated protein C (APC) has a neuroprotective effect. Both proteases interact with protease-activated receptor 1, which exhibits functional selectivity and leads to G-protein- and ß-arrestin-mediated-biased signal transduction. We focused on the effect of ß-arrestin in PAR-1-biased signaling on endothelial function after stroke or high-fat diet (HFD). Thrombin had a rapid disruptive effect on endothelial function, but APC had a slow protective effect. Paralleled by prolonged MAPK 42/44 signaling activation by APC via ß-arrestin-2, a lower cleavage rate of PAR-1 for APC than thrombin was quantitatively visualized by bioluminescence video imaging. HFD-fed mice showed lower ß-arrestin-2 levels and more severe ischemic injury. The expression of ß-arrestin-2 in capillaries and PDGF-ß secretion in HFD-fed mice were reduced in penumbra lesions. These results suggested that ß-arrestin-2-MAPK-PDGF-ß signaling enhanced protection of endothelial function and barrier integrity after stroke.
Subject(s)
Endothelial Cells/metabolism , Proto-Oncogene Proteins c-sis/metabolism , Receptor, PAR-1/metabolism , Stroke/metabolism , beta-Arrestin 2/metabolism , Animals , Cattle , Cells, Cultured , Endothelial Cells/enzymology , HEK293 Cells , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Luminescent Measurements , MAP Kinase Kinase 2/metabolism , Male , Mice , Mice, Inbred C57BL , Neovascularization, Pathologic/metabolism , Phosphorylation , Protein C/metabolism , Proto-Oncogene Proteins c-sis/genetics , Receptor, PAR-1/genetics , Recombinant Proteins/metabolism , Signal Transduction/drug effects , Stroke/enzymology , Stroke/pathology , Thrombin/metabolism , Time Factors , beta-Arrestin 2/geneticsABSTRACT
There are no effective neuroprotectant drugs for acute cerebral ischemia. Serine racemase (SR) synthesizes d-serine, which is involved in N-methyl-d-aspartate (NMDA) receptor-induced neurotoxicity. Recently, SR deletion was reported to protect against focal cerebral ischemia. However, regulatory mechanisms controlling SR-activity in the neurovascular unit (NVU) during cerebral ischemia remain to be clarified. We investigated the effects of SR inhibition on neurovascular protection after ischemia. The SR inhibitor phenazine methosulfate (PMS) alleviated neuronal damage in an ex vivo ischemic model (oxygen glucose deprivation [OGD]) using primary neuronal cultures, and in an in vivo mouse model of ischemia (middle cerebral artery occlusion [MCAO]). Ischemic preconditioning (IP) and PMS-treatment inhibited SR phosphorylation after ischemia ex vivo. In addition, SR phosphorylation after MCAO was also decreased in PMS-treated mice. Reductions in regional cerebral blood flow (CBF) after MCAO were improved by administration of PMS. Treatment with PMS increased phosphorylation of endothelial nitric oxide synthase (eNOS) in the ischemic core and penumbra region. In neuron-endothelial cell co-cultures, PMS promoted nitric oxide production after OGD. These findings indicate that SR inhibition acts as a neuroprotectant in the NVU and ameliorant of CBF abnormalities post-stroke. Thus, pharmacologic SR inhibition has potential clinical applications.
Subject(s)
Brain Ischemia/drug therapy , Methylphenazonium Methosulfate/pharmacology , Neuroprotective Agents/pharmacology , Nitric Oxide/metabolism , Racemases and Epimerases/antagonists & inhibitors , Animals , Brain Ischemia/enzymology , Brain Ischemia/pathology , Cell Hypoxia/drug effects , Cell Hypoxia/physiology , Cell Line , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/enzymology , Cerebral Cortex/pathology , Cerebrovascular Circulation/drug effects , Cerebrovascular Circulation/physiology , Disease Models, Animal , Glucose/deficiency , Male , Mice, Inbred C57BL , Neurons/drug effects , Neurons/enzymology , Neurons/pathology , Nitric Oxide Synthase Type III/metabolism , Phosphorylation/drug effects , Racemases and Epimerases/metabolism , Random Allocation , Rats, WistarABSTRACT
BACKGROUND AND PURPOSE: Leptomeningeal collateral growth is a key factor that defines the severity of ischemic stroke. Patients with stroke generally have vascular risk factors, such as diabetes mellitus; however, consensus is lacking on how diabetes mellitus affects leptomeningeal arteriogenesis. We investigate the influence of diabetes mellitus on the leptomeningeal arteriogenesis. METHODS: We measured the vessel diameter of the leptomeningeal anastomoses 14 days after the common carotid artery occlusion in db/db, db/+, and streptozotocin-induced hyperglycemic mice. In another set of these mice, we measured the infarct volume attributed to subsequent middle cerebral artery occlusion 14 days after the common carotid artery occlusion. Mac-2-positive cells on the dorsal brain surface and the mRNA expression of several macrophage-related factors in the cerebral cortex were examined. Finally, we tested whether the leptomeningeal arteriogenesis could be restored by pharmaceutical intervention in the db/db mice. RESULTS: Cerebral hypoperfusion led to significant ipsilateral leptomeningeal collateral growth in db/+ mice and streptozotocin-induced hyperglycemic mice. The collateral growth contributed to reduced infarct volume. In contrast, leptomeningeal arteriogenesis was impaired in the db/db mice. The number of Mac-2-positive cells was increased and tumor necrosis factor-α mRNA expression was induced after common carotid artery occlusion in the db/+ mice. However, these responses were not observed in the db/db mice. Administration of the tumor necrosis factor-α inhibitor etanercept before common carotid artery occlusion restored the hypoperfusion-induced leptomeningeal collateral growth in db/db mice. CONCLUSIONS: These results indicate that leptomeningeal arteriogenesis is impaired in db/db mice and that suppression of the tumor necrosis factor-α response to hypoperfusion is the major contributing factor.
Subject(s)
Carotid Artery Diseases/blood , Infarction, Middle Cerebral Artery/blood , Neovascularization, Physiologic , Tumor Necrosis Factor-alpha/blood , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carotid Artery Diseases/drug therapy , Carotid Artery Diseases/genetics , Carotid Artery Diseases/pathology , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/pathology , Etanercept , Hyperglycemia/blood , Hyperglycemia/drug therapy , Hyperglycemia/genetics , Hyperglycemia/pathology , Immunoglobulin G/pharmacology , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/genetics , Mice , Mice, Mutant Strains , Receptors, Tumor Necrosis Factor , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/geneticsABSTRACT
The promotion of collateral artery growth is an attractive approach for the treatment of chronic brain hypoperfusion due to occlusive artery disease. We previously reported that hypertension impaired the collateral artery growth of leptomeningeal anastomoses after brain hypoperfusion. Granulocyte colony-stimulating factor (G-CSF) enhances arteriogenesis in a mouse model via a mechanism involving monocyte/macrophage mobilization. However, the arteriogenic effect of G-CSF in hypertension remains unknown. In the present study, we tested whether G-CSF affected collateral artery growth in both normotensive and hypertensive model rat. Left common carotid artery (CCA) occlusion was performed to induce hypoperfusion in the brains of Wistar rats and spontaneously hypertensive rats (SHR). G-CSF was administered subcutaneously for 5 consecutive days. The superficial angioarchitecture of the leptomeningeal anastomoses and the circle of Willis after CCA occlusion and G-CSF treatment were visualized by latex perfusion. Circulating blood monocytes and CD68-positive cells, which represented the macrophages on the dorsal surface of the brain, were counted. G-CSF enhanced leptomeningeal collateral growth in Wistar rats, but not in SHR. G-CSF increased circulating blood monocytes in both Wistar rats and SHR. The number of CD68-positive cells on the dorsal surface of the brain was increased by G-CSF in Wistar rats, but not in SHR. The increase in macrophage accumulation correlated with the observed arteriogenic effects. In conclusion, G-CSF promotes collateral artery growth in the normotensive model rat, but not in the hypertensive model rat.
Subject(s)
Granulocyte Colony-Stimulating Factor/pharmacology , Hypertension/physiopathology , Meninges/blood supply , Meninges/drug effects , Animals , Arteriovenous Anastomosis/drug effects , Carotid Artery Injuries/physiopathology , Circle of Willis/drug effects , Disease Models, Animal , Male , Monocytes/drug effects , Monocytes/metabolism , Rats , Rats, Inbred SHR , Rats, WistarABSTRACT
Endothelial nitric oxide synthase (eNOS) dysfunction is related to secondary injury and lesion expansion after cerebral ischemia. To date, there are few reports about postischemic alterations in the eNOS regulatory system. The purpose of the present study was to clarify eNOS expression, Ser1177 phosphorylation, and monomer formation after cerebral ischemia. Male Wistar rats were subjected to transient focal cerebral ischemia. Endothelial nitric oxide synthase messenger RNA (mRNA) and protein expression increased ≈ 8-fold in the ischemic lesion. In the middle cerebral artery core, eNOS-Ser1177 phosphorylation increased 6 hours after ischemia; however, there was an approximately 90% decrease in eNOS-Ser1177 phosphorylation observed 24 hours after ischemia that continued until at least 7 days after ischemia. Endothelial nitric oxide synthase monomer formation also increased 24 and 48 hours after ischemia (P<0.05), and protein nitration progressed in parallel with monomerization. To assess the effect of a neuroprotective agent on eNOS dysfunction, we evaluated the effect of fasudil, a Rho-kinase inhibitor, on eNOS phosphorylation and dimerization. Postischemic treatment with fasudil suppressed lesion expansion and dephosphorylation and monomer formation of eNOS. In conclusion, functional deterioration of eNOS progressed after cerebral ischemia. Rho-kinase inhibitors can reduce ischemic lesion expansion as well as eNOS dysfunction in the ischemic brain.